Gain Therapeutics reports FY2024 net loss $20.4M; Phase 1b dosing initiated for GT-02287

Gain Therapeutics, Inc.

Net loss of $20.4M ($0.89 EPS) vs $22.3M ($1.71 EPS) in FY2023; revenue not reported.
Cash and securities $10.4M at Dec 31, 2024, down from $16.8M a year earlier.
First patient dosed in Phase 1b trial of GT-02287 for Parkinson's disease; first analysis expected Q2 2025.
Gene Mack appointed President and CEO effective Jan 6, 2025; pre-IND engagement with FDA started.
R&D expenses fell to $10.8M and G&A to $9.6M vs $11.5M and $10.8M in FY2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.